Heart & Estrogen/Progestin Replacement Study (HERS)
Jump to navigation
Jump to search
Introduction
Study characteristics:
- randomized, double-blind, placebo controlled secondary prevention trial
- 2763 women, average age 67 years
- conjugated equine estrogen 0.625 mg + medroxyprogesterone 2.5 mg QD
- mean duration of follow-up 4.2 years
- intention to treat analyses
Results:
- hormone replacement therapy (HRT) did not prevent myocardial infarction fatal or otherwise during a 4 year follow-up
- risk of myocardial infarction acutally increased with HRT during the 1st year
- no evidence that treatment reduced the incidence of fractures or height loss
- reduced risk of developing diabetes mellitus (6% vs 10% over period of 4 years)[5]
More general terms
Additional terms
References
- ↑ Greenwood G. In: Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
- ↑ Cauley JA et al, Am J Med 110:442, 2001
- ↑ Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
- ↑ Journal Watch 23(3):28, 2003 Barnabei VM et al, Obstet Gynecol 100:1209, 2002
- ↑ 5.0 5.1 Journal Watch 23(4):34, 2003 Kanaya AM et al, Ann Intern Med 138:1, 2003